Business Context and Reporting Period
Company: TECHNE Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2004
Business Overview: TECHNE is a holding company with two primary operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, MN, and R&D Systems Europe Ltd. in Abingdon, England. The company operates through three segments: the Hematology Division (blood analysis controls), the Biotechnology Division (cytokines, antibodies, and assay kits for research), and R&D Europe (distribution of biotechnology products in Europe).
Key Financial Metrics
| Metric | Fiscal 2004 | Fiscal 2003 | Fiscal 2002 |
|---|---|---|---|
| Net Sales | $161,257,000 | $145,011,000 | $130,900,000 |
| Gross Margin | 78.4% | 75.6% | 75.2% |
| Operating Income | $82,273,000 | $67,718,000 | $35,074,000 |
| Net Earnings | $52,928,000 | $45,396,000 | $27,130,000 |
| Diluted EPS | $1.27 | $1.08 | $0.64 |
| Operating Cash Flow | $65,553,000 | $54,089,000 | $27,667,000 |
| Cash & Equivalents | $51,201,000 | $39,371,000 | $26,392,000 |
| Total Assets | $325,460,000 | $263,277,000 | $238,247,000 |
| Long-Term Debt | $14,576,000 | $15,852,000 | $17,101,000 |
| Stockholders' Equity | $297,425,000 | $236,617,000 | $206,517,000 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.2% to $161.3 million, driven primarily by a $9.1 million increase in protein and antibody sales and a $5.0 million increase in immunoassay kit sales. R&D Europe sales benefited from favorable foreign exchange rates (approx. $4.0 million impact).
- Margin Expansion: Consolidated gross margin improved to 78.4% from 75.6%. This was largely due to R&D Europe's margin increase (41.8% to 51.4%), driven by favorable exchange rates and the expiration of a 5% royalty agreement with Genzyme.
- Profitability: Net earnings rose 17% to $52.9 million. Operating income increased significantly due to higher sales and improved margins.
- Impairment Charge: The company recorded a $1.5 million impairment loss in the fourth quarter related to its investment in Discovery Genomics, Inc. (DGI), which was written off as "other than temporarily impaired."
- Investment Accounting Change: Following additional financing by ChemoCentryx, Inc. (CCX), TECHNE's ownership dropped to 19.9%, resulting in a shift from the equity method to the cost method of accounting for this investment.
Guidance, Outlook, and Risks
- Outlook: Management expects to meet future cash requirements through available funds and operating cash flow. Capital expenditures for fiscal 2005 are estimated at $2.0 million for equipment. The company plans to add up to 15 research positions in fiscal 2005.
- Investment Risks: The company holds significant investments in early-stage companies (CCX, Hemerus). These investments are subject to impairment risks if the companies fail to secure funding or regulatory (FDA) clearance. The DGI investment was already written off.
- Market Risks:
- Foreign Exchange: Approximately 25% of sales are in foreign currencies. A 10% fluctuation in exchange rates could impact operating income by approximately $1.1 million.
- Research Spending: Revenue is sensitive to government and private research funding levels.
- Competition: Intense competition exists in both hematology controls and biotechnology research markets.
- Legal & Regulatory: The company is involved in a patent interference proceeding with Streck Laboratories regarding hematology controls. It also faces a $1.75 million state tax assessment from Minnesota, which has been appealed.
Key Facts for Investor Verification
- Investment Portfolio Health: Verify the status of the $5.1 million investment in ChemoCentryx and the $2.9 million investment in Hemerus, as both are dependent on future funding and regulatory approvals.
- Foreign Exchange Sensitivity: Monitor the impact of the British Pound and Euro exchange rates on the R&D Europe segment, which contributed significantly to margin expansion in 2004.
- Patent Litigation: Track the outcome of the patent interference action against Streck Laboratories regarding reticulocyte technology.
- Real Estate Expansion: Confirm the timeline and cost completion for the Minneapolis facility infill project (estimated at $8 million) and the exercise of the option for adjacent property expiring January 1, 2005.
- Inventory Valuation: Note that protein and antibody inventory is valued based on a two-year sales forecast; verify if demand volatility impacts future write-downs.